Skip to content

Cardiovascular Risk Assessment in Young Women After Index Pregnancy With and Without Placental Complications

Cardiovascular Risk Assessment in Young Women After Index Pregnancy With and Without Placental Complications

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07356817
Acronym
CARDIOMOM
Enrollment
1260
Registered
2026-01-21
Start date
2023-08-28
Completion date
2026-12-31
Last updated
2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular (CV) Risk, Fetal Weight, Preeclampsia (PE)

Keywords

preeclampsia, Cardiovascular Risk, app

Brief summary

In this project, the investigators aim to study how all these factors determine the cardiovascular status of a total of 1,800 mothers, 3 to 6 years after delivery. In addition, the investigators want to assess whether lifestyle and living conditions after childbirth may improve or worsen this imprint, since women often prioritize their families over themselves, making it more difficult to maintain a healthy lifestyle that could reduce their cardiovascular risk. Furthermore, the investigators will evaluate how environmental exposures influence their health, as well as explore potential strategies for prediction and prevention. The goal is to develop an easy-to-use algorithm or test that allows women and their physicians to assess this risk, ideally in the form of a mobile app. Although predictive algorithms for cardiovascular health already exist, most have been developed using predominantly male or older populations, and none have taken into account pregnancy-related events or environmental exposure - both of which are key determinants of women's cardiovascular health.

Detailed description

Cardiovascular diseases (CVD) are the leading cause of death among women, particularly non-obstructive myocardial infarction, heart failure, and stroke. However, neither women themselves nor, often, their physicians are fully aware of this reality. This lack of awareness is partly due to gender-related myths and biases that have led to insufficient study of the specific causes and risk factors that affect women's cardiovascular systems. Traditionally, it has been assumed that cardiovascular risk mechanisms, prediction, diagnosis, and treatment are the same in men and women. Today, it is known that this is not true: while the severity and mortality due to cardiovascular disease have decreased in men, they continue to rise and remain more severe among women. Reproductive history and hormonal influence play a decisive role in modulating cardiovascular risk in women. Experiencing complications during pregnancy - such as preeclampsia (a hypertensive disorder caused by abnormal placental function), preterm delivery, or the birth of a low-weight infant - increases the risk of cardiovascular complications up to sevenfold later in life, compared with women who had normal pregnancies. This is explained by the fact that the cardiovascular system undergoes major adaptive changes during pregnancy; in complicated pregnancies, these adaptations fail to occur properly, resulting in cardiovascular stress and damage. Among the objectives of this project, the investigators also aim to evaluate other risk factors such as lifestyle and external influences like exposure to environmental pollutants, which may further contribute to cardiovascular vulnerability. Pregnancy represents a critical window of susceptibility - as seen in other conditions such as COVID-19 - during which these environmental and biological impacts on the cardiovascular system are amplified. In this project, the aim is to investigate how all these factors determine cardiovascular health in a cohort of 1,800 mothers, assessed 3 to 6 years after childbirth. The investigators will also examine how postnatal lifestyle and self-care behaviors may either mitigate or exacerbate this imprint. Women often prioritize their families' needs over their own, which can make it difficult to maintain healthy habits that reduce cardiovascular risk. Moreover, the investigators will study how environmental exposures influence maternal health and explore potential predictive and preventive strategies. The goal is to develop an easy-to-use algorithm or test - ideally in the form of a mobile application - to help women and their physicians assess cardiovascular risk. Although predictive algorithms for cardiovascular health already exist, they have mostly been developed in predominantly male or older populations, and none have considered pregnancy-related factors or environmental exposures, both of which are key determinants of women's cardiovascular health. To date, preventive cardiovascular strategies have not been specifically designed for women, and even less so for recently postpartum women. Existing tools have not been adapted for this population. This project brings together obstetricians and cardiologists, as well as midwives and primary care physicians - the healthcare professionals primarily responsible for women's health and well-being. The investigators believe that this multidisciplinary approach is crucial to anticipate cardiovascular disease and implement truly preventive strategies. All study findings will be disseminated through educational sessions for healthcare professionals, new clinical tools and practices to improve patient satisfaction, audiovisual materials for better maternal health communication, and through professional societies (such as SEGO, SEC, SEAP, SEM, etc.). Results will also be published in open-access scientific journals and shared via public outreach, including media coverage, conferences in hospitals and community centers, social media (@DonaSantPau), and the institutional website (http://www.santpau.cat/web/public/go-inici ). The active participation of women in this study will also allow the creation of discussion and advocacy groups among participants, supporting dissemination through social media, online platforms (https://inatal.org), and patient associations (such as El parto es nuestro), as well as newspapers, radio, and television.

Interventions

None listed

Sponsors

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lead SponsorOTHER
Hospital Sant Joan de Deu
CollaboratorOTHER
Barcelona Institute for Global Health
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients who participated in the BiSC (Barcelona Life Study Cohort), EuroPE (Randomized open-label control trial to evaluate if the incorporation of sFlt1/PlGF ratio in the diagnosis and classification of PE improves maternal and perinatal outcomes in women with suspicion of the disease; PI16/00375) and AngioCor (Cardiac dysfunction and remodeling in patients with preeclampsia regulated by antiangiogenic environment: clinical and experimental approach, PI19/00702) cohort studies * Who have delivered within the previous 3-6 years. * Give written consent when invited to participate in this study protocol.

Exclusion criteria

* Unwillingness to participate in this study * Probability of loss to follow-up.

Design outcomes

Primary

MeasureTime frameDescription
Hypertension3-6 years after index pregnancyPresence of hypertension, defined as stage 1 hypertension (SBP of 130-139 or DBP of 80-89 mmHg)
Abnormal cardiac function3-6 years after index pregnancyAbnormal cardiac function in the echocardiographic ultrasound assessment. Abnormal values of the different parameters will be considered according to reference limits published in 2020 by the British Society of Echocardiography
Biochemical cardiac markers3-6 years after index pregnancyAbnormal biochemical cardiac markers: NTproBNP \>300 ng/L or high-sensitivity troponin\>30 ng/L
Coronary artery disease3-6 years after index pregnancySigns of coronary artery disease by computer tomography (CCT) myocardial perfusion imaging (mild (CACS≥10 AU and \<100 AU); moderate (CACS≥100 AU and \<400 AU) and severe (CACS ≥400 AU)
Other cardiovascular major events3-6 years after index pregnancyCardiovascular major events (ictus, coronary artery disease, cardiac insufficiency or myocardiopathy)

Secondary

MeasureTime frameDescription
Age3-6 years after index pregnancyPatient age
Pregnancy complications3-6 years after index pregnancyPreeclampsia, pregnancy complications, presence of fetal distress, perinatal mortality, neonatal morbidity, and neonatal mortality.
Antrophometric measurements3-6 years after index pregnancyPercentages of body fat, muscle mass, visceral fat
Blood pressure3-6 years after index pregnancySystolic and Dyastolic blood pressure
Computer tomography (CCT) myocardial perfusion imaging and RM Quantitative Myocardial Perfusion3-6 years after index pregnancyAllows an accurate and reliable assessment of both coronary epicardial stenosis and myocardial CT perfusion imaging at rest and during pharmacologic stress in the same examination. CCT will be performed with a 256-slice CT scanner (Philips Healthcare scanner) with prospective ECG-triggering as previously described. First, a noncontrast CCT will be performed to calculate the CACS using the Agatston scoring method. Second, CCTA will be performed following sublingual nitroglycerin and injection of nonionic contrast (Iopromide, Ultravist, Bayer Healthcare, Berlin, Germany). The presence of any coronary plaque (noncalcified, calcified, or mixed) and the presence of significant stenosis (≥50%) was assessed in all 17 coronary segments. One of 2 assigned and experienced cardiovascular radiologists assessed the CT scans for each participant.
Cardiovascular markers in maternal blood3-6 years after index pregnancyVenous blood samples will be collected without anticoagulant to obtain serum. Troponin T and NTproBNP will be measured in ng/ml using automated electrochemiluminescence immunoassays on the Roche Cobas platform (Roche Diagnostics GmbH, Mannheim, Germany).Intra-and interassay coefficients of variation were found to be \<5%.
Laboratory data measured in mg/dl3-6 years after index pregnancyglucose, uric acid, creatinine, VLDL, LDL, HDL, total cholesterol, triglycerides
Cardiovascular assessment according to IBERLIFERISK score3-6 years after index pregnancyA score \>50% is considered as a high-risk for CVD.
Hair sampling for cortisol determination3-6 years after index pregnancyHair samples will be cut with scissors from the region of the posterior vertex, as close to the scalp as possible. Considering that hair grows approximately 1 cm per month, 3 cm will be obtained in order to evaluate hair cortisol levels representative of the last 3 months. Samples will be stored (in a dark container at room temperature) until analysis by liquid chromatography mass spectrometry.
Diet and nutrition3-6 years after index pregnancyevaluated by means of the Short Diet Quality Screener by REGICOR (registre Gironí del Cor) and by means of the validated 14-item questionnaire of adherence to the Mediterranean diet. Escale from 1-31. The highest the score, the highest the adherence to the mediterranean diet.
Physical activity3-6 years after index pregnancyevaluated by means of the Physical Activity Questionnaire by REGICOR, a validated questionnaire for quantifying physical activity in our population. The short questionnaire estimates energy expenditure in total PA and by intensity (light, moderate, vigorous), and includes 2 questions about sedentary behavior and a question about occupational PA.
Stress3-6 years after index pregnancyevaluated by the Perceived Stress Scale (PSS) Questionnaire, validated for quantifying perceived stress in our population. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived this: Scores ranging from 0-13 would be considered low stress. Scores ranging from 14-26 would be considered moderate stress. Scores ranging from 27-40 would be considered high perceived stress.
Mental health3-6 years after index pregnancyevaluated by the Psychiatric Diagnostic Screening Questionnaire (PDSQ), a brief, psychometrically strong, self-report scale designed to screen for the most common disorders encountered in outpatient mental health settings and validated in our population. The final version of the questionnaire contains 13 subscales (major depressive disorder \[MDD\], bulimia, post-traumatic stress disorder \[PTSD\], panic disorder, agoraphobia, social phobia, generalized anxiety disorder \[GAD\], obsessive-compulsive disorder \[OCD\], alcohol abuse/dependence, drug abuse/dependence, somatization, hypochondriasis, and psychosis). Additionally, there is a six-item psychosis screen.
Smoking habit3-6 years after index pregnancyevaluated by the Fagerström Questionnaire, validated questionnaire for quantifying dependence on smoking in our population.
Women experiences and eHealth3-6 years after index pregnancyFor this aim, a team of anthropologists with a long experience in the fields of health and reproduction will use qualitative methods to understand the needs of women with and without CV risk after pregnancy. To this end, semistructured interviews will be undertaken with patients with low and high risk of CV disease. These interviews will be useful to have a deep understanding of the difficulties, desires, and needs in relation to interactions with practitioners and available services in healthcare settings. For proactive monitoring and follow-up of patients, a technological platform or App (CardioPlan), currently used for cardiac rehabilitation, will be restructured, which has a highly secure data repository located on the provider's server and then validated in a subgroup of patients (n=100).
BMI3-6 years after index pregnancyWeight and height will be combined to report BMI in kg/m\^2
Waist/Hip ratio3-6 years after index pregnancyMeasurements in cm2 of waist and hip to calculate waist/hip ratio in cm2
Heart rate3-6 years after index pregnancyMeasured in hpm
Echocardiographic assesment3-6 years after index pregnancyPerformed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High-resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis.
Myocardial deformation (strain)3-6 years after index pregnancymeasured by echocardiography is increasingly recognized as a more effective technique than conventional ejection fraction (EF) in detecting subtle changes in left ventricular (LV) function and in predicting outcomes. AutoStrain TOMTEC Philips EPIQ CVx ultrasound systemwould be used for the analysis.
Carotid intima-media thickness3-6 years after index pregnancyTransverse longitudinal evaluation of the common carotid artery, its bifurcation and internal carotid artery. Thickness of the intima layer is measured at the middle third of the common carotid artery and is considered the measurement between the tunica intima and tunica media, the innermost two layers of the wall of an artery.
ophthalmic artery evaluation3-6 years after index pregnancyThe woman is placed in a supine position to rest for 5 minutes. A 7.5-MHz linear transducer is then placed transversely and gently over her closed upper eyelid after application of conduction gel. Color flow Doppler is used to identify the ophthalmic artery, which is found superior and medially to the hypoechoic band representing the optic nerve. Pulsed-wave Doppler is then used to record 3 to 5 similar waveforms. Doppler studies are performed twice in each eye, and the average of the 4 measurements is used for analysis.
Laboratory data measured in g/l3-6 years after index pregnancyVenous blood samples and urine samples will be collected to measure hemoglobin and protein in urine
Laboratory data measured in l/l3-6 years after index pregnancyVenous blood samples will be collected to measure hematocrit
Laboratory data measured in U/mcl3-6 years after index pregnancyVenous blood samples will be collected to measure leukocytes and platalets
Laboratory data measured in mmol/l3-6 years after index pregnancyVenous blood samples will be collected to measure potassium and sodium
Laboratory data measured in %3-6 years after index pregnancyVenous blood samples will be collected to measure glicated hemoglobin
Laboratory data measured in U/L3-6 years after index pregnancyVenous blood samples will be collected to measure alanine transaminases, aspartate aminotransferases and lactate dehydrogenase
Laboratory data measured in mg/l3-6 years after index pregnancyUrine samples will be collected to measure albumin
Laboratory data measured in mUI/l3-6 years after index pregnancyVenous blood samples will be collected to measure tirotropin and prolactin
Ethnicity3-6 years after index pregnancyPatient ethnicity
Smoking status3-6 years after index pregnancyPatient smoking status
Menstrual type3-6 years after index pregnancyPatient menstrual type and presence of menopause
Diseases3-6 years after index pregnancyDiabetes, obesity, and other maternal diseases associated with cardiovascular risk
Interval from index preganancy3-6 years after index pregnancyinterval in years from index pregnancy.
Gestational age at delivery3-6 years after index pregnancyGestational age at delivery in index pregnancy
Mode of delivery3-6 years after index pregnancymode of delivery at index pregnancy,
Labor induction3-6 years after index pregnancylabor induction at index pregnancy
Child's gender3-6 years after index pregnancyChild's gender in index pregnancy
Birth weight percentile3-6 years after index pregnancybirth weight percentile in index pregnancy
Birth weight3-6 years after index pregnancyChild's birth weight at index pregancy.
APGAR score3-6 years after index pregnancy5-minute Apgar score in index pregnancy. Apgar score measures appareance, pulse, grimance, acivity and respiratory effort. For each chriteria newborns can receive a punctuation from 0 to 2, qhere 2 is the better punctuation.
Blood preassure during pregnancy3-6 years after index pregnancyBlood preassure druing index pregnancy
Weight during pregnancy3-6 years after index pregnancyWeight during index pregnancy.

Countries

Spain

Contacts

CONTACTElisa Llurba Olivé, PhD
ellurba@santpau.cat+34 935534078
CONTACTPablo García Manau, PhD
pgarciama@santpau.cat+34 627813346
PRINCIPAL_INVESTIGATORElisa Llurba, PhD

Hospital de la Sant Creu i Sant Pau

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026